-
Kenya's economy faces climate change risks: World Bank
-
Bitter communion: Cuban priests ordered to ration mass wafers
-
In crisis-hit Cuba, World Cup offers brief respite
-
UK intercepts Russian shadow fleet vessel in Channel
-
London, Tokyo agree $24-bn investment deal
-
Indonesian economy comes up for air but struggles to win back investors
-
Trump says US-Iran deal to be signed Sunday, Hormuz to open after
-
Between Trump and a hard place: Fed chair Warsh to lead first rate meeting
-
High-school drop out to big time crime boss, Venezuela's 'Nino Guerrero'
-
US-Iran deal could be finalised soon, mediator Pakistan says
-
Thousands gather in Thai capital to mourn late princess
-
US says downed multiple Iran drones as both insist deal closer
-
SpaceX: Five key moments, from first launch to Starship megarocket
-
US clears Paramount's $111 bn Warner Bros. takeover
-
Iran and US say deal closer than ever
-
Cuba opens more sectors to private business
-
World Cup struggles to ignite US excitement
-
US appellate court upholds Sam Bankman-Fried criminal sentence
-
France bids farewell to girl, 11, whose killing sparked outrage
-
Wall Street wobbles as SpaceX shares launch, oil slides on Mideast deal hopes
-
SpaceX lifts off in record Wall Street debut
-
US deportation flight carrying Iranians en route to C.African Republic
-
At a Libyan university once ravaged by war, students dream again
-
Kenya mourns schoolgirls killed in suspected dorm arson attack
-
Stocks rally, oil slides on Mideast deal hopes
-
'All of us of are migrants,' pope says in Canary Islands
-
Switzerland split on immigration vote: four perspectives
-
Thai princess dies aged 47 after three years in hospital
-
Science fiction? Musk's lofty SpaceX goals unrealistic, skeptics say
-
Asia stocks up, oil down on Mideast deal hopes
-
From cage fights to the White House, UFC marches into mainstream
-
Pope ends Spain visit with migrant meetings
-
Ex-Tottenham owner sells art collection in blockbuster auction
-
Antarctic Peninsula sees record high June temperatures
-
US stocks rally, oil prices fall as Trump calls off fresh Iran strikes
-
SpaceX to make historic IPO that could make Musk a trillionaire
-
El Nino is back, but its effects vary widely
-
First leather bag from T-Rex cells to be auctioned in Paris
-
Four times as many icebergs calved from Greenland glaciers: study
-
Stocks rebound, oil wavers as traders weigh Iran, rates outlook
-
Niger criminalises same-sex relations with jail terms
-
Smuggled dinosaur fossils return to Mongolia after two decades
-
Over 260 Nigerians fleeing xenophobic attacks in S. Africa return home
-
Pope condemns 'indifference' towards migrants on Canaries trip
-
Sweden withdraws controversial proposal to jail 13-year-olds
-
Economic pressures 'manageable': Indonesian deputy finance minister
-
Scientists warn of record heat, threats to climate monitoring
-
Sweden withdraws disputed proposal to jail 13-year-olds
-
UK probes Ryanair over fees for parents to sit with children
-
Suspense surrounds Swiss anti-immigration vote
Ozempic slimming craze sweeps Kosovo despite side effects
Kosovo influencer Tringa Kadriu sees the slimming drug Ozempic as a chance to shed excess pounds -- and she is not the only one in her Balkan nation, where more than half the population is overweight.
"I want to lose 15-16 kilos (33-35 pounds) in two months," Kadriu, 29, told AFP, "and then I'll continue with fitness".
Ozempic, approved in the United States to treat diabetes in 2017, has found an international market for people trying to lose weight.
Despite its cost, the drug has soared in popularity in Kosovo, a country of 1.7 million.
While Kosovo authorities have not sanctioned the drug's use for weight loss, they have noted their limited means to confront use of a drug widely available in the country.
Merita Emini-Sadiku, who heads the Kosovo university hospital's endocrinology clinic, said the cost of the drug had soared.
"The monthly dose used to be 75-80 euros ($85-91), while now it is 130-140 euros ($147-159), probably due to high demand," she said.
But she warned that "Ozempic has side effects that people are not aware of".
Ozempic use can potentially cause issues including thyroid cancer, pancreatitis, gastroparesis and bowel obstruction, according to the latest studies.
- 'Constant demand' -
Meant to treat Type 2 diabetes -- of which the WHO says Kosovo has lower than average levels -- the drug regulates blood sugar levels but also helps suppress hunger, leading to a lower calorie intake.
As a result, its potentially cancerous complications have done little to stem the drug's popularity or availability.
"I checked a lot of pharmacies in Kosovo and I noticed that Ozempic is very easy to get," said Kadriu, adding that pharmacists even suggested she gradually increase her dosage.
A worker at a pharmacy in the capital Pristina's downtown, who asked to remain anonymous, said she had trouble recalling when someone last came into her pharmacy to buy Ozempic with a diabetes prescription.
"But we have a constant demand for Ozempic without a prescription. You can guess why," she said.
Given its availability, Emini-Sadiku said authorities should exercise greater control over Ozempic's distribution.
But Bujar Vitija, a journalist specialising in health, said that would be tricky to achieve given Kosovo's poor health record-keeping.
"Unfortunately there is no data," Vitija said.
With 1,500 to 1,600 private pharmacies in Kosovo, the country's 20 pharmaceutical inspectors have their work cut out for them, he added.
- Ozempic 'every day' -
While Kosovo has lower levels of obesity than the European average, more than 57 percent of the population is overweight and 20 percent is clinically obese, according to a 2019 World Health Organization report.
And women, who are more likely to face societal pressure to be thin, were 66 percent more likely to be obese than men, the WHO report found.
But not every Kosovar who has used Ozempic had the best experience with the drug.
"I took Ozempic on the advice of a doctor for two years but it had no effect," said 48-year-old merchant Lulzim Rrahmani, adding that three of his relatives even experienced "a negative effect of the drug".
"It was just a waste of money and time."
Given the risk of side effects, Emini-Sadiku said Ozempic was "by no means to be taken without a doctor's prescription".
Yet Kadriu said she would not be deterred, adding that she saw colleagues taking the drug "every day at work".
"I don't see any symptom that would deter me."
X.Wong--CPN